Development of an ultrasensitive immunoassay for human glandular kallikrein with no crossreactivity from prostate-specific antigen

Clinical Chemistry

Volumn 45, Issue 6 I, 1999, Pages 790-799

  Black, Margot H ^a,b   Magklara, Angeliki ^a,b   Obiezu, Christina V ^a,b   Melegos, Dimitrios N ^a   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER SCREENING; CLINICAL LABORATORY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE DISEASE;

EID: 0033065627     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.6.790     Document Type: Article

References (25)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Clements JA. The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrinol 1994;99:C1-6.
3. Montie JE, Meyers SE. Defining the ideal tumor marker for prostate cancer. Urol Clin N Am 1997;24:247-52.
4. Oesterling JE. Prostate specific antigen: a clinical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
5. Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol 1993;11:188-91.
6. Young CYF, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992;31:818-24.
7. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of the pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-4.
8. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238:549-55.
9. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. J Biol Chem 1997;272: 21582-8.
10. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
11. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980;40:2428-32.
12. Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998;51:804-9.
13. Christopoulos T, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992;64:342-6.
14. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultra-sensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite® immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996;42:675-84.
15. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
16. Henttu P, Vihko P. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. Ann Med 1994; 26:157-64.
17. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998;34: 44-50.
18. Saedi MS, Cass MMJ, Goel AS, Grauer L, Hogen KL, Okaneya T, et al. Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies. Mol Cell Endocrinol 1995;109:237-41.
19. Lovgren J, Piironen T, Overmo C, Dowell B, Karp M, Pettersson K, et al. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995;213:888-95.
20. Corey E, Buhler KR, Vessella RL. Cross-reactivity of ten antiprostate-specific antigen monoclonal antibodies with human glandular kallikrein. Urology 1997;50:567-72.
21. Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B, et al. Immunofluorometric assay for sensitive and specific measurement of human prostate glandular kallikrein (hK2) in serum. Clin Chem 1996;42:1034-41.
22. Charlesworth MC, Young CF-Y, Klee GG, Saedi MS, Mikolajczyk D, Finlay, Tindall DJ, Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 1997;49:487-93.
23. Christensson A, Laurell CB, Lilja H. Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 1990;194:755-63.
24. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R. In prostatism patients, the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/mL. Urology 1998;52:360-5.
25. Chapdelaine P, Paradis G, Tremblay RR, Dube JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-8.